LAMEA Carrier Screening Market By Technology (DNA Sequencing, Microarrays, Polymerase Chain Reaction and Other technology), By End user (Hospital and Clinics, Physician Offices, Reference Laboratories and Other End Users), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Carrier Screening Market
Market Report Description
The Latin America, Middle East and Africa Carrier Screening Market would witness market growth of 11.47% CAGR during the forecast period (2021-2027).
Predictive/presymptomatic testing refers to the identification of the risk, before the beginning of the symptoms. The majority of the genetic disorders can be identified early during the pregnancy stage. Hence, the growth of the overall carrier screening market would be driven by the high consumer demand for secure and efficient carrier tests. Additionally, the market would be benefitted commercially due to the massive adoption of carrier tests into regular clinical care. As per many studies, early detection of diseases can avoid them wholly or at least reduce the complexities of the diseases. Healthcare firms in numerous countries are funding newborn screening to foresee the possibilities of diseases such as cancers, which would happen later in adulthood.
The growing demand for advanced healthcare systems or devices in the region is expected to create bright prospects for regional growth. Along with this, the increasing disposable income of consumers in some emerging nations of this region would also contribute to the demand for advanced diagnosis methods like carrier screening due to their willingness to spend high on different healthcare solutions.
In addition, the rising focus of many manufacturers of the region on improving the technologies will also help them to create advanced and cost-effective carrier screening procedures that would further positively impact the growth of the regional carrier screening market.
The Brazil market dominated the LAMEA Other End user Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $3.1 million by 2027. The Argentina market is showcasing a CAGR of 15.5% during (2021 - 2027). Additionally, The UAE market is anticipated to grow at a CAGR of 14.1% during (2021 - 2027).
Based on Technology, the market is segmented into DNA Sequencing, Microarrays, Polymerase Chain Reaction and Other technology. Based on End user, the market is segmented into Hospital and Clinics, Physician Offices, Reference Laboratories and Other End Users. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics, Incorporated, Thermo Fisher Scientific, Illumina, Inc., Eurofins Scientific Group, Invitae Corporation, OPKO Health, Inc., Fulgent Genetics, Sema4 OpCo, Inc., Myriad Genetics, Inc., and Natera, Inc.
Scope of the Study
Market Segments Covered in the Report:
- Expanded Carrier Screening and
- Targeted Disease Carrier Screening
- DNA Sequencing
- Polymerase Chain Reaction and
- Other technology
By End User
- Hospital and Clinics
- Physician Offices
- Reference Laboratories and
- Other End Users
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Quest Diagnostics, Incorporated
- Thermo Fisher Scientific
- Illumina, Inc.
- Eurofins Scientific Group
- Invitae Corporation
- OPKO Health, Inc.
- Fulgent Genetics
- Sema4 OpCo, Inc.
- Myriad Genetics, Inc.
- Natera, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free